Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.19 USD
Change Today 0.00 / 0.00%
Volume 0.0
GALTU On Other Exchanges
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics - uts (GALTU) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/12/14 - $16.25
52 Week Low
09/2/15 - $3.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

galectin therapeutics - uts (GALTU) Related Bloomberg News

View More Bloomberg News

galectin therapeutics - uts (GALTU) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics - uts (GALTU) Details

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase 1/2 clinical trials in Belgium as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

7 Employees
Last Reported Date: 03/18/15
Founded in 2000

galectin therapeutics - uts (GALTU) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $698.4K
Executive Chairman and Executive Vice Preside...
Total Annual Compensation: $324.0K
Chief Financial Officer
Total Annual Compensation: $213.5K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $307.6K
Compensation as of Fiscal Year 2014.

galectin therapeutics - uts (GALTU) Key Developments

Galectin Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Galectin Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total operating loss of $4.657 million compared to $3.375 million a year ago. Net loss applicable to common stock was $4.931 million or $0.21 per diluted share compared to $3.731 million or $0.17 per diluted share a year ago. For six months, the company reported total operating loss of $9.497 million compared to $8.219 million a year ago. Net loss applicable to common stock was $10.005 million or $0.43 per diluted share compared to $9.139 million or $0.42 per diluted share a year ago.

Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02

Exalenz Bioscience Ltd. announced that it received FDA approval for a joint clinical trial with Galectin Therapeutics Inc. The company's product, the BreathID, will be used to track and diagnose patients in a second-stage clinical trial of GR-MD-02, an experimental treatment for liver cirrhosis caused by NASH (fatty liver disease). Galectin Therapeutics is conducting a multicenter, double-blind, placebo-controlled Phase 2 trial with 156 patients to evaluate the safety and effect of the drug.

Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development

Galectin Therapeutics Inc. announced the appointment of Adam E. Allgood, Pharm.D., R.Ph. as executive director of clinical development, effective immediately. Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at UCB Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALTU:US $5.19 USD 0.00

GALTU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALTU.
View Industry Companies

Industry Analysis


Industry Average

Valuation GALTU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS - UTS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at